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Atopic dermatitis (AD) is a common, chronic or chronically relapsing, severely pruritic, eczematous skin disease. AD is the second 
most frequently observed skin disease in dermatology clinics in Japan. Prevalence of childhood AD is 12-13% in mainland Japan; 
however, it is only half that (about 6%) in children from Ishigaki Island, Okinawa. Topical steroids and tacrolimus are the mainstay of 
treatment. However, the adverse effects and emotional fear of long-term use of topical steroids have induced a “topical steroid pho-
bia” in patients throughout the world. Undertreatment can exacerbate facial/periocular lesions and lead to the development of atopic 
cataract and retinal detachment due to repeated scratching/rubbing/patting. Overcoming topical steroid phobia is a key issue for the 
successful treatment of AD through education, understanding and cooperation of patients and their guardians.
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INTRODUCTION
Atopic dermatitis (AD) is a common, chronic or chronically 
relapsing, severely pruritic, eczematous skin disease. The 
incidence of AD is generally considered to be increasing 
worldwide [1, 2]. The percentage of adolescent- and adult-type 
AD has also been increasing [3, 4]. The etiology and pathogenesis 
of AD are not fully delineated. Recent studies demonstrate that 
it involves a complex interaction of skin barrier dysfunction, 
exposure to external allergens or microbes, Th2-prone response 
and psychosomatic reaction. Intense itching, skin inflammation, 
and other atopic symptoms impose a remarkable burden on the 
individual and society.
The history of AD is very old. Prior to the nomenclature of 
“atopic dermatitis” by Sulzberger et al. [5] in 1933, the disease 
was reported under various dermatological terms such 
as neurodermite diffusa (Brocq), lichen chronicus simplex 
disseminatus (Vidal), pruritus with lichenification, allergic eczema, 
hay-fever eczema and flexural eczema; each one highlighted 
important clinical aspects of this disease. Helmont (1607) and 
Trousseau (1850) pointed out a close association between asthma 
and certain types of pruritic skin disorder, and Vidal (1880) 
described a characteristic distribution of itchy lichenified plaques 
in this disease [5, 6]. Brocq and Jacquet (1891) referred to the 
disease as neurodermite diffusa, emphasizing its psychosomatic 
nature; later on, the disease was commonly reported in 
literature under the term neurodermatitis (neurodermitis) 
diffusa or disseminate, neurodermatitis constitutionalis, and 
disseminated neurodermatitis [7]. In 1892, Besnier named the 
disease “diathésique eczémato-lichénienne”, mentioning that 
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most cases first develop as infantile eczema with severe pruritus 
at predilection sites such as the face, neck, and perioral and 
flexural regions, and they are closely related with asthma and 
hay fever [5, 8]. Since then, the term “prurigo Besnier” has often 
appeared in literature, especially in Europe. In 1923, Coca and 
Cooke [9] first reported that asthma and hay fever are specifically 
compartmentalized in individuals or family members who were 
hypersensitive to various external antigens, and they proposed 
the use of the term “atopy” for these mysterious phenomena. 
Meanwhile, the close association of certain types of itchy eczema 
with asthma and hay fever again drew special attention by Low 
as an eczema-asthma-prurigo complex or by Drake as an asthma-
eczema-prurigo complex in 1928 [8, 10], leading to the proposal of 
“atopic dermatitis/eczema” [5, 11, 12]. Even in the early 1930s, basic 
concepts for AD had been postulated: 1) family history of atopy; 
2) antecedent infantile eczema; 3) preponderance on antecubital 
and popliteal fossae, anterior neck, chest, face and eyelids; 4) 
skin hyperpigmentation; 5) no appreciable vesicle formation as is 
usually clinically and histologically found in contact dermatitis; 6) 
unstable or hypersensitive vasomotor neuron reaction; 7) negative 
patch test reaction to most contact allergens; 8) positive skin 
test reaction to various environmental and food allergens; and 9) 
positive serum reaginic activity (=IgE) as detected by Prausnitz-
Küstner reaction [11-13].
Genetic and environmental factors are apparently involved 
in the onset and exacerbation of AD in a mutually interactive 
manner. In 1993, Schultz Larsen et al. [14] reported that the 
pairwise concordance rate of AD in monozygotic twin pairs 
was 72% while it was only 23% in their dizygotic counterparts. 
They also noted that the prevalence of AD increased sharply 
from 3.2% in 1960-1964 to 10.2% in 1970-1974. Interestingly, the 
results of a similar study published in 1971 indicated that the 
concordance rate seemed to be affected by the prevalence rate 
even in genetically identical twins [15]. In the 6996 pairs of twins 
with a 4.3% AD prevalence rate, the pairwise concordance rate of 
AD was only 15.4% and 4.5% in the monozygotic and dizygotic 
twins, respectively [15]. AD-inducing environmental factors, as 
yet unknown, had increased their power in industrialized and 
developing countries and seemed to trigger the onset of AD in 
almost all individuals who were genetically predisposed to the 
disease.
Incidence of AD in dermatological clinics in Japan
Masuda reported that the incidence of AD in outpatient clinics 
was 4.1% in 36,233 patients who visited the Dermatology Clinic of 
the University of Tokyo from 1959 to 1961. In the Branch Hospital 
of the University of Tokyo, the incidence of AD in our first-visit 
patients was 5.6% (195/3,491) in 1967, 8.7% in 1976 (277/3,188), 
7.7% (224/2,913) in 1986 and 10.1% (261/2,586) in 1996 [16]. 
Considering the results of previous reports on the incidence of AD 
in dermatological outpatient clinics [2.3% (Drake, 1928, London), 
0.6% (Nexmand, 1926-1935, Copenhagen), 1.4% (Nexmand, 1936-
1945, Copenhagen), 0.32-1.53% (Iijima & Saito, 1938-1955, Sendai), 
1.4% (Ofuji, 1954-1956, Kyoto), 7% (Hellerström & Rajka, 1953-
1959, Karolinska), and 8.3% (Uehara & Ofuji, 1977, Kyoto)], AD had 
become a very common skin disease during the 1950s through 
1970s in industrialized countries [16]. Another interesting point 
was the age distribution of AD patients. In 1967, 73.9% of AD 
patients were 0-9 years old at the Branch Hospital of the University 
of Tokyo, but this figure gradually dropped to 23.4% by 1996. In 
contrast, the percentage of AD patients 20-29 years old was 3.1% 
in 1967, and markedly increased to reach 38.7% by 1996 [16]. Adult-
type AD patients at dermatological clinics have clearly increased 
recently (Fig. 1) as pointed out by Sugiura et al. [4].
In order to clarify the current prevalence of skin disorders among 
dermatology patients in Japan, the Japanese Dermatological 
Fig. 1. Age distribution of outpatients with atopic dermatitis at the Branch 
Hospital, University of Tokyo.apallergy.org
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Association conducted a nationwide, cross-sectional, seasonal, 
multicenter study in 2007-2008 [17]. Among the 67,448 cases, the 
top twenty skin disorders were, in descending order of incidence, 
miscellaneous eczema, AD, tinea pedis, urticaria/angioedema, 
tinea unguium, viral warts, psoriasis, contact dermatitis, acne, 
seborrheic dermatitis, hand eczema, miscellaneous benign skin 
tumors, alopecia areata, herpes zoster/postherpetic neuralgia, 
skin ulcers (nondiabetic), prurigo, epidermal cysts, vitiligo vulgaris, 
seborrheic keratosis, and drug eruption/toxicoderma (Table 1). The 
incidence of AD was 9.8% without any gender difference. The age 
distribution of AD was biphasic, peaking at 0-5 years old and 21-35 
years old (Fig. 2) [17]. Patients older than 46 years comprised 9.6% 
(649/6,733) of all AD patients [17].
Incidence of AD in the general population in Japan
The incidence of AD in Japanese elementary school students 
was around 3% in 1981-1983 but increased to around 6-7% in the 
1990s [3]. Yura and Shimizu conducted a questionnaire survey 
of health symptoms in four million school children (aged 7-12 
years) in Osaka and reported that the lifetime prevalence of AD 
increased from 15.0% in 1985 to 24.1% in 1993 but leveled off 
thereafter (22.9% in both 1995 and 1997) [18]. Their subsequent 
study also confirmed the consecutive decrease of AD prevalence 
from 1993 to 2006 (16.5%) [19]. Meanwhile, the prevalence of 
wheezing was constant at 3.0 ± 0.1% between 1975 and 1983, 
and then increased to 4.7% in 1993. It restabilized at 4.4 ± 0.3% 
between 1993 and 2006 [19]. The prevalence of rhinitis increased 
from 12.3% in 1983 to 16.7% in 1991, increased further to 25.4% 
in 2003, and then leveled off at 24.7% in 2006 [19]. The reported 
prevalence of AD of Japanese children is summarized in Table 2.
From 2000 to 2002, the research team of the Japanese Ministry 
of Health, Labour and Welfare (chief researcher: Dr. S. Yamamoto) 
examined 48,072 children living in Asahikawa, Iwate, Tokyo, Gifu, 
Osaka, Hiroshima, Kochi, and Fukuoka [20]. They reported that the 
national average prevalence rate of AD was 12.8% in 4-month-
old children, 9.8% in 18-month-olds, 13.2% in 3-year-olds, 11.8% 
in 6- to 7-year-olds, 10.6% in 12- to 13-year-olds, and 8.2% in 
18-year-olds [20]. In 2001, we started a population-based survey 
of children aged 5 years and younger in Ishigaki Island, Okinawa, 
Japan (Kyushu University Ishigaki Dermatitis Study; KIDS). The 
prevalence of childhood AD in this southern subtropical island 
was as low as around 6% [21, 22] and did not increase during the 
period from 2001 to 2010 (unpublished data).
Regression rate of AD
It is well documented that AD regresses spontaneously, 
especially in infants and children. Kawaguchi et al. [23] reported 
that out of 102 4-month-old patients, 83 regressed spontaneously 
Fig. 2. Age distribution of atopic dermatitis in dermatology clinics. Report 
from the Japanese Dermatological Association (n = 6,733).
Table 1. Top 20 diseases in dermatology clinics in Japan (n = 67,448)
1 Eczema (miscellaneous) 12,590 18.67%
2 Atopic dermatitis 6,733 9.98%
3 Tinea pedis 4,379 6.49%
4 Urticaria / angioedema 3,369 4.99%
5 Tinea unguim 3,231 4.79%
6 Viral warts 3,028 4.49%
7 Psoriasis 2,985 4.43%
8 Contact dermatitis 2,643 3.92%
9 Acne vulgaris 2,430 3.60%
10 Seborrheic dermatitis 2,213 3.28%
11 Hand eczema 2,024 3.00%
12 Benign skin tumors (miscellaneous) 1,666 2.47%
13 Alopecia areata 1,653 2.45%
14 Herpes zoster / Postherpetic neuralgia 1,609 2.39%
15 Skin ulcer (non-diabetic) 1,334 1.98%
16 Prurigo 1,229 1.82%
17 Epidermoid cysts 1,194 1.77%
18 Vitiligo vulgaris 1,134 1.68%
19 Seborrheic keratosis 1,095 1.62%
20 Drug eruption / Toxicoderma 1,018 1.51%
Total  57,557 85.34%
Japanese Dermatological Association (2007).apallergy.org
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by 18 months old. Illi et al. [24] reported that the cumulative 
prevalence of AD in the first 2 years of life was 21.5%. Among 
these children with early AD, 43.2% were in complete remission by 
the age of 3 years, 38.3% had an intermittent pattern of disease, 
and 18.7% had symptoms of AD every year. Severity (adjusted 
cumulative odds ratio, 5.86; 95% CI, 3.04-11.29) and atopic 
sensitization (adjusted cumulative odds ratio, 2.76; 95% CI, 1.29-
5.91) were major determinants of prognosis of AD [24]. In our KIDS 
cohort, 71.6% (53/74) of AD patients under 5 years old regressed 
spontaneously, whereas 5.5% (44/795) of non-AD individuals 
developed AD during the 3-year followup. Increases in total IgE 
levels were greater and more rapid in children with long-term AD 
compared to those who had spontaneously regressed, had newly 
developed AD or did not have AD [22]. Anan and Yamamoto 
reported that 287 out of 1,072 6-year-old children in Nagasaki had 
a present (91) or past history (196) of AD in 1995, that is, 68.3% 
(196/287) of AD children experienced spontaneous regression by 
age 6 [25]. They also followed up on 50 AD children of 6 years old 
and found that 30 children had spontaneously regressed within 
the subsequent 6 years [25]. In Hiroshima, mean prevalence of AD 
children of 6 years old from 1992 to 1997 was 13.6% (male: 13.6%, 
female: 13.7%; total number 1,327) [26]. Among 121 children of 
6 years old with AD, 61 were cured and 22 had improved 5 years 
later. Among 464 non-AD pupils of 6 years old, 6 (1.3%) had AD 5 
years later [26]. Williams and Strachan analyzed the age of onset 
and clearance rates for examined and/or reported eczema in 
6,877 children born during the period 3-9 March 1958 for whom 
linked data was available at birth and at the ages of 7, 11, 16 and 
23 years. Of the 870 cases with examined or reported eczema by 
the age of 16 years, 66% had experienced onset by the age of 7 
years. Of the 571 children with reported or examined eczema by 
the age of 7 years, the proportion of children who were clear in 
terms of examined or reported eczema in the last year at ages 11 
and 16 years was 65% and 74%, respectively. These ‘apparent’ or 
short-term clearance rates fell to 53% and 65%, respectively, after 
allowing for subsequent recurrences in adolescence and early 
adulthood [27]. Uehara et al. [28] examined the regression rate of 
266 AD cases (older than 2 years of age at the first visit in 1953 to 
1961) in 1966 (5 to 13 years later) by questionnaire. They reported 
that AD was cured in 76 cases (29%). In the 190 uncured cases, 
40 cases experienced a short regression of more than a year’s 
duration. Of these 40 cases, 36 (90%) reported that their transient 
regression appeared within 15 years after the onset of AD, and 
29 cases (79%) reported that their transient regression did not 
last more than 5 years [28]. Another questionnaire study revealed 
that either transient or complete remission occurred in 33.3% of 
794 AD patients (10-20 years old) [29]. In a mail-in questionnaire 
study, 220 AD patients (mean age: 21.3 ± 11.8) were monitored 
every 3 months by for 3 years from 2006 to 2009. Thirty-six (16.4%) 
patients reported having at least a year’s remission. Four cases 
developed atopic cataract (12, 13, 54 and 59 years old) during 
this period and none of the four had experienced any remission. 
Patients older than 30 years had a significantly lower remission rate 
compared to those younger than 30 years [30]. 
Table 2. Prevalence of atopic dermatitis in Japan
6-10 years 12-13 years 14-15 years
1981-83 Aichi     3.85% 1.96%
1990 Osaka, questionnaire 19% 9.2% 9.0%
1992 West Japan (11 Prefs., questionnaire)     17.3%
1993 Hirosaki 9% 9.2%
1993 Hamamatsu 24.3%
1995 Nagasaki 8.5%
1996 Ibaragi 7.6%
1992-97 Hiroshima, Asa area 13.7%
2001 Hiroshima 10.9%
2001 Maebashi 9.9%
2002 Isahaya 10.1%
2002 West Japan (11 Prefs., questionnaire)    13.8%
2000-02 All Japan, 8 cities 11.8% 10.6%apallergy.org
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The regression of adult-type AD tends to occur more slowly. 
Our 95 cases of adult AD (mean age 23.9 ± 11.5 in 1991-1992, 
male: 45, female: 50) reported the following in 1996: AD was cured 
(10.5%), much improved (32.6%), slightly improved (34.7%), and 
unchanged or worse (22.1%). Eleven patients reported that the 
onset of AD was as late as 18 years or older. Association with other 
allergic disease significantly lowered the regression/improvement 
rate compared to the pure AD group [31]. The severity of AD also 
increased according to age. Yamamoto demonstrated that the 
percentage of mild cases decreased gradually with age (84.3% 
at 1.5 years old, 85% at 3 years old, 75.9% at 6 years old, 71.6% at 
12 years old and 72.7% at 18 years old), while the percentage of 
moderate cases increased inversely (12.4% at 1.5 years old, 11.8% at 
3 years old, 22.4% at 6 years old, 26.3% at 12 years old and 21.9% at 
18 years old) [20]. This phenomenon can be caused by numerous 
aggravating factors including hormonal imbalance in adolescence, 
increased physical and schoolwork stress, and emotional stress 
related to social and family issues. Decreased compliance with 
treatment regimens may also contribute to the deterioration of AD.
Topical steroid therapy with special reference to steroid phobia 
in Japan
Although topical steroids, emollients and oral antihistamines 
are used as the first-line therapy for AD, long-term application, 
even with intermittent use, induces local and unavoidable adverse 
effects such as skin atrophy and telangiectasia in a substantial 
percentage of patients. These adverse effects and the emotional 
fear of long-term use of topical steroids have induced a topical 
steroid phobia in patients throughout the world [32].
Before the topical tacrolimus was commercially available in 
Japan, we collected clinical data on 1,271 AD patients who had 
been followed for at least 6 months in outpatient clinics [33]. The 
check sheet for each patient included the following items: age; 
gender; duration of AD; global severity before treatment; global 
severity after 6 months of conventional topical steroid therapy; 
evaluation of clinical improvement; total dose of each rank of 
topical steroids per 6 months’ therapy on the face, scalp, trunk 
and extremities; association with herpes simplex infection and/
or Kaposi’s varicelliform eruption; association with molluscum 
contagiosum; and adverse effects of topical steroids (telangiectasia 
on cheeks, skin atrophy of antecubital/popliteal fossae, acne and 
folliculitis, hypertrichosis, bacterial infection, dermatomycosis,   
rosacea-like dermatitis, contact dermatitis caused by topical 
steroids, and steroid-induced striae atrophicae). Global clinical 
severity was classified as “very severe”, “severe”, “moderate” and 
“mild”. The ranking of topical steroids was “strongest”, “very 
strong”, “strong”, “mild” and “weak” in Japan.
The 1,271 patients with AD were divided into 3 groups according 
to age: 210 infantile (0-2 year old) cases, 546 childhood (≥2 and 
<13 years old) cases, and 515 adolescent and adult (≥13 years 
old) cases. All of the patients were treated with topical steroids 
and moisturizing emollients. The clinical severity of AD in the 
majority of patients improved or was unchanged after 6 months 
of conventional therapy (“controlled” group). However, 7% of 
infantile AD, 10% of childhood AD and 19% of adolescent and 
adult AD patients remained in a very severe or severe state or 
experienced exacerbation (“uncontrolled” group) (Table 3) [33]. 
This data suggested that the incidence of very severe and severe 
AD was significantly higher in the adolescent/adult AD group than 
in the infantile and childhood groups. Concordantly, Brunsting 
pointed out in 1936 that the recurrent lesions of adolescent and 
adult AD were resistant to treatment by local measures [34]. These 
Table 3. Change of clinical severity pre- and post-treatment
Pre-treatment
Infantile AD
* Childhood AD Adolescent & Adult AD
Very 
severe Severe Moderate Mild Very 
severe Severe Moderate Mild Very 
severe Severe Moderate Mild
post-
treatment
Very severe 3 2 15 2
Severe 8 1 5 27 3 6 65 6
Moderate 2 9 41 6 5 44 155 11 7 58 161 4
Mild 6 57 76 1 17 141 117 2 21 92 64
undescribed 1 1 2 6 1 1
Total  (207) 2 23 99 83 (540)14 91 301 134 (505)31 147 259 68
 Uncontrolled patients per 6 months. Infantile: 7%. Childhood: 10%. Adolescent & Adult: 19%. 
*AD: atopic dermatitis.apallergy.org
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uncontrolled patients were considered as “intractable” and they 
received much attention as a social problem in Japan.
The total doses of topical steroids used during the 6-month 
treatment period are listed in Table 4 as median, 75 percentile and 
90 percentile doses. During the 6 months, 90% of AD patients 
used less than 89.5 g, 135 g and 304 g of topical steroids on the 
entire body in the infantile, childhood, and adolescent/adult 
groups, respectively. The 90 percentile doses applied on the face 
during the 6 months were 10 g, 15 g and 35 g in the infantile, 
childhood and adolescent/adult AD groups, respectively. The 
amount of topical steroids applied in this survey was much less 
than that reported by Wilson et al. and Munro et al. [35, 36]. 
Association with herpes simplex virus infection and/or Kaposi’s 
varicelliform eruption was found in 2.4% of infantile AD patients, 
2.5% of childhood AD patients and 3.5% of adolescent and adult 
AD patients during the 6-month treatment period. Association 
with molluscum contagiosum was detected in 7% of infantile AD 
patients, 9% of childhood AD patients, and 0.2% of adolescent 
and adult AD patients. The cumulative incidence of adverse effects 
was assessed (Table 5) and as expected, it was much higher 
in the adolescent and adult AD patients than in the infantile 
AD patients. Telangiectasia on the cheeks and skin atrophy of 
antecubital/popliteal fossae were frequently observed as the 
predilection sites of AD (face and flexure areas). There was a small 
but appreciable percentage of patients with adverse effects such 
as local skin atrophy and telangiectasia [33]. The incidence of these 
adverse effects might be predicted by age, sex, and strength and 
quantity of topical steroids. In addition, these adverse effects were 
reversible [37].
We next examined the topical steroid doses used in the 
“controlled” and “uncontrolled” groups (Table 6) [33]. The 
total usage of topical steroids was unexpectedly higher in the 
“uncontrolled” group than in the “controlled” group. The statistical 
difference became more obvious in the adolescent/adult group 
than in the childhood group (Table 3). Topical steroids are useful for 
treating AD, but there appears to be a subgroup of patients who 
remain severe despite increasing applications of topical steroids. 
Nevertheless, all of the patients in the “uncontrolled” group may 
not have been “uncontrollable”, because the total application dose 
per 6 months in 50% of the “uncontrolled” patients was very small 
(Table 6, undertreatment state). Undertreatment may cause or 
enhance the development of the “uncontrolled” group. The most 
popular tube size of topical steroids is 5 g in Japan, which is much 
smaller than European and American tubes (Fig. 3). This may, at 
Table 4. Clinical doses of topical steroids during 6 months of treatment (g)
Infantile  Childhood Adolescent & 
Adult
No. of cases 210 546 515
Face
50% dose
75% dose
90% dose
1
5
10
0
5
15
0
15
35
Scalp
50% dose
75% dose
90% dose
0
0
10
0
0
10
0
0
65
Body
50% dose
75% dose
90% dose
21
40
74.5
45
80
130
80
160
280
Total
50% dose
75% dose
90% dose
25
43
89.5
45
80
135
95
180
304
 
Table 5. Adverse effects of topical steroids
Infantile  Childhood Adolescent & 
Adult
Teleangiectasia of cheeks 0% 2.3% 13.3%
Skin atrophy of antecubital fossae 1.5% 5.2% 15.8%
Skin atrophy of popliteal fossae 1.9% 4.1% 9.8%
Acne / folliculitis 0% 1.3% 8.2%
Hypertrichosis 0.5% 1% 2.7%
Bacterial infection 1.4% 2.1% 2.5%
Fungal infection 1.9% 0.6% 1.2%
Rosacea-like dermatitis 0% 0.4% 3.1%
Contact dermatitis 0% 0.4% 0.8%
Striae cutanea 0% 0% 1%apallergy.org
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least in part, contribute to topical steroid undertreatment in Japan. 
Suitable amounts of topical steroid application, such as the finger-
tip-unit dose [38], may markedly decrease the percentage of the 
“uncontrolled” group. Various social, economic and ecological 
factors together with the medical insurance system may affect 
“steroid phobia”-related undertreatment.
Atopic cataract is another important issue that may be 
misunderstood by AD patients. Brunsting first described atopic 
cataract in detail in 1936 [34]. He demonstrated the frequent 
association of juvenile cataract with AD in 10 out of 101 AD 
patients (mean age: 22 years old) [34]. He then performed an 
ophthalmological check in 1,158 AD patients from 1940 to 1953, 
and found typical atopic cataract in 136 patients (11.7%) including 
79 cases of visual disturbance [39]. He also pointed out that the 
rapid progression of atopic cataract in adolescent- and adult-type 
AD was usually associated with the exacerbation of skin eruption 
[34, 39]. The incidence of atopic cataracts in Japanese AD patients 
is also around 10-15% in the literature. Importantly, steroids were 
not available as medication until 1949 to 1952 [40]. These facts 
emphasize that atopic cataract is a distinct clinical sign of AD, and 
is likely induced by repeated scratching/rubbing/patting of facial 
and periocular lesions and is not directly related to steroids [41-
44]. Retinal detachment and subsequent blindness are also serious 
ophthalmological complications [42].
CONCLUSION
AD is a very common skin disease in dermatology clinics in 
Table 6. Dose of topical steroids between controlled and uncontrolled groups
Total doses “Strongest + very strong 
+ strong” dose “Mild + weak” dose
Controlled
group
Uncontrolled
group
Controlled 
group
Uncontrolled
group
Controlled 
group
Uncontrolled
group
No   191   15   191   15 191 15
Infantile
50% dose
75% dose
90% dose
         20 (g)
   40
   70
        30 (g)
  60
  90
           5 (g)
  25
45.8
          0 (g)
  15
  72
          5 (g)
  20
  40
      20 (g)
40
59
Mann-Whitney’s U-test 0.3002 0.3427 0.0496
No   481    51  481    51  481   51
Childhood
50% dose
75% dose
90% dose
         40 (g)
   75
120
         60 (g)
120
207.8
         25 (g)
  60
100
        24 (g)
  75
 151
          0 (g)
  20
51.6
       10 (g)
40
99
Mann-Whitney’s U-test 0.0018 0.2895 0.0003
No  406    98  406   98 406  98
Adolescent &
Adult
50% dose
75% dose
90% dose
         75 (g)
150
 250
      140 (g)
252.5
400.5
         60 (g)
 120
 225
   117.5 (g)
230
245
          0 (g)
    0
56.5
         0 (g)
   0
75.5
Mann-Whitney’s U-test 0.0000 0.0000 0.1918
Fig. 3. In Japan, 5-g tubes are typically used in daily clinics. Larger tubes 
(100 g or 50 g) are more commonly used in Europe and the USA.
Europe & USA:
100 g, 
50 g
Japan: 5 gapallergy.org
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Japan. The English version of the guidelines for management and 
severity of AD by the Japanese Dermatological Association have 
been published in literature [45-47], the principals of which are 
identical to those of other academic societies. AD affects patients 
across several generations with different disease activity. Genetic, 
environmental and emotional factors are variably involved in the 
onset and clinical course of AD. It is also a challenging task to 
fight against topical steroid phobia in daily clinics. Therefore, the 
Japanese guideline for AD includes many practical instructions 
for the patients [45]. Education, understanding and cooperation 
of patients and their guardians are a key issue for the successful 
treatment of AD.
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